[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603095":3},{"organization":4,"outcomesModule":7,"designInfo":18,"detailedDescription":24,"studyPopulation":17,"armGroups":25,"interventions":32,"overallOfficials":37,"centralContacts":44,"locations":17,"responsibleParty":51,"collaborators":17,"id":53,"slug":17,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":56,"acronym":17,"eligibilityCriteria":57,"healthyVolunteers":54,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":17,"studyType":64,"phases":65,"briefSummary":66,"conditions":67,"keywords":69,"overallStatus":73,"whyStopped":17,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":17},{"fullName":5,"class":6},"Clinica Universidad de Navarra, Universidad de Navarra","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":17},[9],{"measure":10,"description":11,"timeFrame":12},"Overall Survival","A. To achieve a 1-year survival of 85%.","2-years",[14],{"measure":15,"description":16,"timeFrame":12},"Adverse Events","To decrease grade 4-5 gastrointestinal events to less than 5%.",null,{"allocation":19,"interventionModel":20,"interventionModelDescription":17,"primaryPurpose":21,"observationalModel":17,"timePerspective":17,"maskingInfo":22},"NA","SINGLE_GROUP","TREATMENT",{"masking":23,"maskingDescription":17,"whoMasked":17},"NONE","The implementation of Magnetic Resonance Image Guided Radiotherapy (MRgRT) into a Pancreatic Cancer Intensification Program maximizes treatment objectives rates due to the better visualization and online dose-adaptation pancreatic tumor.\n\nRationale In the radiation setting, MRI provides superior soft tissue contrast compared to standard onboard X-ray imaging improving inter- and intra- observer delineation variation. MRgRT offers the opportunity to adapt the plan at each fraction to the anatomical changes seen (Henke et al., 2018). This creates a much better CTV to OAR ratio in a 50Gy\u002F5Rx scenario.\n\nPrimary Objectives A. To achieve a 1-year survival of 85%. B. To decrease grade 4-5 gastrointestinal events to less than 5%.\n\nSecondary Objectives A. Determination of blood and urine biomarkers of treatment response and toxicity .\n\nB. Determination of radiomics biomarkers of treatment response and toxicity . C. Determination of quality of life with the EORTC QLQ-C30 Questionnaire .",[26],{"label":27,"type":28,"description":29,"interventionNames":30},"Ultrahypofractionation Phase","EXPERIMENTAL","MR-Guided Ultrahypofractionation",[31],"Radiation: MR-guided Irradiation",[33],{"type":34,"name":35,"description":35,"armGroupLabels":36,"otherNames":17},"RADIATION","MR-guided Irradiation",[27],[38,42],{"name":39,"affiliation":40,"role":41},"Rafael Martínez-Monge, M.D.","Clínica Universidad de Navarra","PRINCIPAL_INVESTIGATOR",{"name":43,"affiliation":40,"role":41},"Luis Fuertes, M.D.",[45],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Beatriz Ramos Aguirre, M.S.","CONTACT","+34 948255400","2772","ucicec@unav.es",{"type":52,"investigatorFullName":17,"investigatorTitle":17,"investigatorAffiliation":17,"oldNameTitle":17,"oldOrganization":17},"SPONSOR","100603095",false,"NCT07132060","MRI-guided Dose Intensification Program Locally Advanced Pancreatic Cancer","Inclusion Criteria:\n\n* Selection criteria includes patients with unresectable and borderline resectable and medically inoperable pancreatic cancer that will receive neoadjuvant chemotherapy followed by chemoirradiation.\n* No prior radiation therapy to the target areas;\n* Karnofsky performance status \\> 70 with medical condition not contraindicating treatment with radical intent including neoadjuvant chemotherapy followed by chemoirradiation.\n* WBC equal or greater than 3500 mm\\^3; platelet count equal or greater than 135000 mm\\^3; hemoglobin equal or greater than 10 gr\u002FL; BUN equal or less than 20; serum creatinine equal or less than 2.0.\n\nExclusion Criteria:\n\n* Inability to undergo an MRI scan","ALL","18 Years","80 Years",{"count":62,"type":63},30,"ESTIMATED","INTERVENTIONAL",[19],"The goal of this clinical trial is to learn if the use of dose-escalated MRI-guided irradiation increases the rates of disease control in patients with pancreatic cancer",[68],"Pancreatic Cancer",[70,71,72],"MRI-guided irradiation","Dose escalation","Ultrahypofractionation","NOT_YET_RECRUITING","2025-08-20",{"date":76,"type":77},"2025-08-27","ACTUAL",{"date":79,"type":63},"2025-10-01",{"date":81,"type":63},"2030-06-30",{"name":5,"class":6}]